PR Newswire (Fri, 4:15PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,259 people get ACT articles and Market Currents by email alert.
Get email alerts on ACT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Actavis Confirms Appeals Court Issues Injunction Related to Generic Pulmicort RESPULES® DistributionPR Newswire (Fri, 4:05PM)
-
-
-
-
-
-
-
-
-
PR Newswire (May 14, 2013)
-
PR Newswire (May 13, 2013)
-
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 10, 2013)
-
PR Newswire (May 9, 2013)
-
-
PR Newswire (May 7, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
Watson Is Still Strong Despite A Slowing Generic Drug MarketFreedonia Freelance • Tue, Dec 11, 2012 -
-
-
-
-
Watson Pharmaceuticals: Earnings PreviewZacks Investment Research • Tue, Jul 24, 2012 -
-
-
-
-
Accretive Acquisitions Likely For Watson PharmaceuticalsTakeover Analyst • Sun, Oct 9, 2011
-
Watson Benefits From New PartnershipsJim Van Meerten • Wed, Jun 22, 2011
-
Watson Pharmaceuticals Earnings PreviewZacks Investment Research • Tue, Apr 26, 2011
-
Watson Pharmaceuticals: In-Depth Analysis for the December 2010 QuarterNeil Carvin • Sun, Feb 20, 2011 -
Watson Pharmaceuticals: Looking Ahead to December 2010 Quarterly ResultsNeil Carvin • Fri, Dec 31, 2010
-
Watson Investors Come Out Losers in CEO SubpoenaPharmalot • Mon, Dec 6, 2010 -
-
Watson Pharmaceuticals, Inc. - Shareholder/Analyst CallTue, Jan 24, 2012
-
Watson Pharmaceuticals Q2 2010 Earnings Call TranscriptThu, Aug 5, 2010
-
Watson Pharmaceuticals Q1 2010 Earnings Call TranscriptMon, May 10, 2010
-
Watson Pharmaceuticals, Inc. Q4 2009 Earnings Call TranscriptTue, Feb 23, 2010
-
Watson Pharmaceuticals Q3 2009 Earnings Call TranscriptWed, Nov 4, 2009
-
Actavis Confirms Appeals Court Issues Injunction Related to Generic Pulmicort RESPULES® DistributionPR Newswire (Fri, 4:05PM)
-
at CNBC.com (Wed, 5:41AM)
-
at MarketWatch.com (Mon, 4:38PM)
-
at MarketWatch.com (Mon, 4:33PM)
-
at CNBC.com (Mon, 4:27PM)
-
at CNBC.com (Mon, 8:48AM)
-
at MarketWatch.com (Mon, 8:46AM)
-
at Fox Business (Mon, 7:30AM)
-
at Fox Business (Mon, 7:30AM)
-
at Fox Business (Mon, 7:23AM)
-
at CNBC.com (May 16, 2013)
-
PR Newswire (May 14, 2013)
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 13, 2013)
-
at MarketWatch.com (May 10, 2013)
-
PR Newswire (May 10, 2013)
-
PR Newswire (May 9, 2013)
-
PR Newswire (May 7, 2013)
ACT vs. ETF Alternatives
Company Description
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug,... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, April 30, 2012, 7:33 AM Watson Pharmaceuticals (WPI): Q1 EPS of $1.64 beats by $0.04. Revenue of $1.52B (+73.9% Y/Y) beats by $40M. (PR) Comment! [Earnings, Healthcare]
- Monday, April 30, 2012, 12:05 AM Notable earnings before Monday’s open: BWP, CNA, HUM, L, LYB, NYX, SNH, SOHU, UDR, WPI Comment! [Earnings]
- Sunday, April 29, 2012, 5:30 PM Notable earnings before Monday’s open: BWP, CNA, HUM, L, LYB, NYX, SNH, SOHU, UDR, WPI Comment! [Earnings]
- Thursday, April 26, 2012, 1:20 PM Watson Pharmaceuticals (WPI +6.6%) gets a lift today after agreeing to acquire Swiss rival Actavis. The purchase gives the company a boost in the global rankings of generic drug makers to the number 3 spot. Citigroup upgrades the stock to Buy on the news. Comment! [Healthcare, On the Move, M&A]
-
Thursday, April 26, 2012, 9:20 AM
Premarket gainers: PATK +26%. HTWR +15%. REGN +14%. NUAN +14%. LOGI +14%. VHC +12%. CTXS +12%. NRGY +10%. EQIX +9%. CRUS +8%. SPPI +8%. INCY +7%. XLNX +7%. WPI +7%. AMRN +5%. EA +7%. MWW +5%. AH +6%. PHM +6%. AIS +5%. AIXG +5%. LSI +4%. TS +3%. UN +3%. ZNGA +3%. FRO +3%. RDS +3%.
Losers: FURX -28%. PCS -15%. HRB -15%. TQNT -14%. ALU -13%. TSPT -12%. AET -9%. PTX -7%. AKAM -6%. AZN -6%. ZMH -5%. DB -5%. HERO -5%. STD -5%. DOW -4%. CELG -4%. CS -4%. CROX -4%. GG -3%. BWA -3%. UNH -3%. LVS -3%. VALE -3%. UPS -3%. POT -3%. Comment! [On the Move] - Wednesday, April 25, 2012, 4:56 PM Watson Pharmaceuticals (WPI) confirms it will buy Actavis Group for at least €4.25B euros ($5.60B), in a deal that cements its status as one of the world's biggest suppliers of generic drugs. WPI +5.5% AH. Comment! [Healthcare, M&A]
- Monday, April 23, 2012, 4:03 PM Watson Pharmaceuticals (WPI +0.1%) is close to announcing a $5.6B deal for Actavis by Wednesday, according to sources. The deal is an important one for Deutsche Bank (DB -3.6%), which was left holding billions of euros of Actavis debt after a leveraged buyout in 2007. Comment! [Healthcare, M&A]
- Wednesday, April 18, 2012, 2:56 PM Valeant Pharmaceuticals (VRX +0.1%) and DepoMed (DEPO +3.0%) sue Watson Pharmaceuticals (WPI +0.2%) over its generic glumetza diabetes drug, according to reports. Sales of Glumetza are tipped to reach more than $100M this year. Comment! [Healthcare]
- Friday, April 13, 2012, 10:58 AM Watson Pharmaceuticals (WPI +0.1%) sees bank line up to help finance the firm's $6B takeover of Actavis. Source say the initial structure of a proposed agreement is for a $2B term loan and a $4B bridge loan, with BoA the frontrunner to lead the deal. Comment! [Healthcare]
- Wednesday, April 11, 2012, 12:23 PM Watson Pharmaceuticals (WPI +1.3%) is on track to announce a deal to buy Swiss-based Actavis for ~$6B by the end of April, creating one of the world's biggest producers of generic drugs, Reuters reports. Watson believes a move would help it compete more effectively against rivals like Teva and Novartis unit Sandoz. Comment! [M&A, Healthcare, On the Move]
- Tuesday, April 10, 2012, 8:17 AM Watson Pharmaceuticals (WPI) receives FDA approval for a generic version of Vancocin and plans to begin shipping the products immediately. Comment! [Healthcare]
- Wednesday, March 21, 2012, 11:45 AM Watson Pharmaceuticals (WPI +0.8%) bounces around violently after word leaks that the company is close to signing off on a deal to buy Icelandic firm Actavis for €5B-€5.5B. Shares dropped sharply off the news, then reversed themselves in a slingshot move higher, and now stand +0.6%. Comment! [M&A, On the Move, Global & FX, Healthcare]
- Thursday, March 15, 2012, 2:58 PM Mylan (MYL +1.4%) has pulled out of discussions to buy a stake in Italian pharmaceutical firm Rottapharm after the selling family wouldn't agree to give up control, nor compromise enough on price. Rottapharm has also held talks with Watson Pharmaceuticals (WPI -0.2%) and Forest Labs (FRX +0.1%), however Watson doesn't appear likely to be a buyer. Comment! [Healthcare, Global & FX]
- Friday, March 2, 2012, 10:36 AM Watson Pharmaceuticals (WPI -0.3%) confirms that it launched a generic version of Prometrium as part of an agreement with Abbott Laboratories (ABT +0.1%). Over the last 12-month reporting period, Prometrium had sales of close to $198M. Comment! [Healthcare]
- Monday, February 27, 2012, 7:21 AM Watson Pharmaceutical (WPI) confirms that it received a complete response letter from the FDA spelling out concerns over its progesterone vaginal gel designed to reduce the risk of preterm births. The letter states that the treatment doesn't meet the level of statistical significance expected to support the approval of a product from a single trial. Comment! [Healthcare]
- Tuesday, February 14, 2012, 9:02 AM More on Watson (WPI +2.2%) Q4: Net income more than quintuples to $94.8M, with earnings boosted by generic versions of Pfizer's Lipitor cholesterol treatment and J&J's Concerta ADHD drug. Watson ups its 2012 EPS guidance to $5.50-$5.80 from $5.25-$5.55 and vs. $5.60 consensus. Also ups rev forecast by $100M to $5.4B. Comment! [Earnings, Healthcare]
-
Michael Kudrna
Biotech: Watson Pharma (ACT) Notes From Credit Suisse Webcast 11/9/2011 http://bit.ly/rsiy6K/ - View all 0 replies
-
- View all 0 replies
-
Michael Bryant
Carbo Ceramics (CRR), Dollar Tree Stores (DLTR), and Watson Pharmaceuticals (ACT) look buys. Perrigo (PRGO), maybe. http://on-msn.com/nz0k7t - View all 0 replies
-
Jim Van Meerten
ACT - 100% Barchart technical buy signal - 1 new highs and up 6.09% in the last month with a Relative Strenght Indedx of 65.06% and rising - View all 0 replies
-
MagicDiligence
Par Pharma - Buried in the Generic Drugs Battlefield $PRX $TEVA $ACT $MYL $NVS http://stk.ly/kB9i9C - View all 0 replies
-
Justin M. Hall
ZIOP, NBY, EBS, ABT, PRXL, CERN, ACT, CBRX => Notable Developments and Results 12/6/10 => Rx Investors.com => http://bit.ly/c9Kc5C - View all 0 replies
-
Smart-Ticker.com
Top Bears $CROX,$TRW,$CMO,$ACT,$PCG,$NSM-RETIRED,$LOGI,$ADBE,$OMI,$MCHP...more http://s-t.cc - View all 0 replies
-
Jim Van Meerten
ACT -- Watson Pharma -- 100% Barchart buy signal -- acquisition of Arrow give then new overseas markets for their generic drug distribution - View all 0 replies
-
MagicDiligence
Magic Formula stock review: Endo Pharmaceuticals $ENDP $ACT $TEVA - http://bit.ly/bCxeNV - View all 0 replies
-
- View all 0 replies
LATEST REPLIES